Ascendis Pharma Reports Q3 Revenue Growth of 90.7% Year-over-Year
Ascendis Pharma A/S (ASND) has reported its third-quarter financial results, highlighted by a significant surge in revenue reaching €369.6 million. This represents a substantial year-over-year increase of 90.7%, driven largely by the continued expansion and commercial momentum of its TransCon platform. The company also posted a Non-GAAP Earnings Per Share (EPS) of €1.71 for the quarter. These results follow recent positive sentiment from analysts, including an 'outperform' rating from BMO regarding the growth potential of its core technology platform.
Tickers: $ASND $BMO $JNJ $LLY $MS $PFE